Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received a consensus recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $6.8750.

A number of equities analysts have issued reports on the company. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a report on Friday, July 17th.

Institutional Investors Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare in the fourth quarter valued at approximately $77,000. Jane Street Group LLC acquired a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $79,000. Ingalls & Snyder LLC acquired a new position in shares of Sensus Healthcare during the 4th quarter worth approximately $219,000. State Street Corp raised its stake in Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after acquiring an additional 3,400 shares during the period. Finally, North Star Investment Management Corp. acquired a new stake in Sensus Healthcare during the 1st quarter valued at $500,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Down 3.1%

Sensus Healthcare stock opened at $2.85 on Thursday. The company has a 50 day moving average of $2.95 and a 200-day moving average of $3.81. Sensus Healthcare has a twelve month low of $2.66 and a twelve month high of $5.92. The stock has a market capitalization of $46.91 million, a PE ratio of -6.06 and a beta of 1.09.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $3.39 million for the quarter, compared to analyst estimates of $5.32 million. Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.